Bulletin of Stomatology and Maxillofacial Surgery
ISSN 1829-006X
2025; 589–596
Shared with The Gufo

ACUTE AND CHRONIC HERPES ZOSTER INFECTION MEDICAL TREATMENT: STILL A ROLE FOR INNATE IMMUNITY MODULATION

Palmieri B*, Vadalà M., Calogero Bugea

Medical Network, Street Ciro Bisi, 125, 41124 Modena, Italy · Medico Cura Te Stesso Onlus, Street Ciro Bisi, 125,41124, Modena, Italy · University of Chieti–Pescara, 66100 Chieti, Italy;

Received: 2025-12-24 · Published: 2025-11-19

© 2025 The Author(s) and the original publisher.

CC BY-NC 4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Shared article.

Originally published in Bulletin of Stomatology and Maxillofacial Surgery, 2025 — https://doi.org/10.58240/1829006X-2025.21.10-589.

Original title
ACUTE AND CHRONIC HERPES ZOSTER INFECTION MEDICAL TREATMENT: STILL A ROLE FOR INNATE IMMUNITY MODULATION
Authors
Palmieri B, Vadalà M., Calogero Bugea
Source journal
Bulletin of Stomatology and Maxillofacial Surgery
Published
2025-11-19
Licence
Creative Commons Attribution-NonCommercial 4.0 International
Original
https://doi.org/10.58240/1829006X-2025.21.10-589

Abstract

Background: The updated treatment of acute and chronic zoster infections encloses antiviral, painkillers neuropathic drugs for postherpetic neuralgia, anti-inflammatory compounds and vaccines. The persistent viability of the virus into the posterior horns of the medulla, makes its virulence highly resistant to the current protocols and suggests a reconsideration of an old bacteriotherapy enhancing the innate immunity and direct phagocytosis of the virus at any stage: the inactivated Cutibacterium acnes, formerly Corynebacterium parvum. The aim of this study is to counter Zoster neuropathic pain with Corynebacterium parvum. Materials and Methods: A total of 300 patients were treated using C.parvum injection (2.5 cc of Parvulan added with 0.3 ml 1% lidocaine), in the subcutaneous deltoid area at any stage, affected by primary dermatomal zoster (64 cases), by genital Zoster (16 cases), by first infection (34 cases), by frequently relapsing primary zoster (14 cases), by Zoster neuralgia (46 cases), by Zoster infection in patients with cancer (32 cases), by cancer under chemotherapy [62 cases (46 men and 16 women)], by Zoster infection in severe immunodepression (28 cases), by Zoster encephalomyelitis (4 cases). Results: Chronic neuralgia was successfully alleviated in most treated patients in a few weeks after the treatment. Conclusion: in conclusion in the setting of zosteridae family side to the most updated pharmacology, we still recommend to take into account also an old historical weapon such as the C. parvum bacteriotherapy, because of its safe and effective direct antiviral activity.
1 / ? 100% Open in new tab Download Cite

Loading the full text…

Download Follow Updates